SPY415.87+4.42 1.07%
DIA340.44+2.91 0.86%
IXIC14,038.76+180.92 1.31%

Veeva Highlights First Patient Completion Of Consent For Phase 2b Study

Veeva eConsent makes it easier for patients to understand and provide electronic informed consent Milestone accelerates industry's move toward paperless, patient-centric trials Veeva Systems (NYSE:VEEV) today

· 03/16/2021 07:11

Veeva eConsent makes it easier for patients to understand and provide electronic informed consent

Milestone accelerates industry's move toward paperless, patient-centric trials

Veeva Systems (NYSE:VEEV) today announced that Veeva eConsent, a MyVeeva for Patients application built on Veeva Clinical Network, had its first patient complete an electronic consent for an early phase clinical trial by Crofoot Research Center. Veeva eConsent is the first validated application for sites and patients that transforms the consent process from manual and paper-based to an end-to-end digital experience. Patients can review documents and protocols and provide consent via mobile phone, streamlining the experience for both patients and sites.